PLI.TO - Prometic Life Sciences Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.0300
+0.0050 (+20.00%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close0.0250
Open0.0300
Bid0.0250 x 0
Ask0.0300 x 0
Day's Range0.0250 - 0.0300
52 Week Range0.0200 - 1.0100
Volume1,159,122
Avg. Volume4,292,081
Market Cap696.564M
Beta (3Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-0.2660
Earnings DateMay 12, 2017 - May 15, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.13
  • CNW Group2 days ago

    Prometic announces completion of equity rights offering

    LAVAL, QC , ROCKVILLE , MD  and CAMBRIDGE, United Kingdom , June 17, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") is pleased to confirm the completion of its previously announced equity rights offering, raising aggregate gross proceeds of C$37,998,000 (or the equivalent of US$ 28,357,000 ) (the "Rights Offering"). Following the Rights Offering, 23,218,813,405 common shares of the Corporation are issued and outstanding.

  • PR Newswire5 days ago

    Prometic Presents New Data on PBI-4050 and its Mechanism of Action on Kidney Fibrosis at the 56th ERA/EDTA Congress

    LAVAL, QC , ROCKVILLE , MD and CAMBRIDGE, United Kingdom , June 14, 2019 /PRNewswire/ -  Prometic Life Sciences Inc.  (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing ...

  • Reuters14 days ago

    CANADA STOCKS-TSX edges lower as energy offsets materials boost

    Canada's main stock index edged lower on Wednesday, as gains in shares of materials companies were outweighed by a decline in the energy sector. * At 9:54 a.m. ET (1354 GMT), the Toronto Stock Exchange's S&P/TSX Composite index was down 10.31 points, or 0.06%, at 16,155.93. * The energy sector dropped 0.5%, weighing the most on the main index, as oil prices resumed their slide, dragged down after an unexpected gain in U.S. inventories.

  • PR Newswire20 days ago

    Prometic Life Sciences to Present at Two Upcoming June Investor Conferences

    LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, May 30, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced that members of the management team will provide a business overview and update at the 2019 Jeffries Global Healthcare Conference at 14:30 EDT on Thursday, June 6, 2019 and at the Raymond James Life Sciences & MedTech Conference at 15:35 EDT on Wednesday, June 19, both in New York, NY. Prometic (www.prometic.com) is an innovative biopharmaceutical corporation with a broad pipeline of small molecule therapeutics under development to treat unmet needs in patients with liver, respiratory and kidney disease, including rare diseases.

  • CNW Group28 days ago

    Prometic presents new PBI-4050 and Ryplazim™ (plasminogen) data on lung fibrosis at the 2019 ATS Conference

    LAVAL, QC and CAMBRIDGE, United Kingdom , May 22, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced the presentation of three scientific posters on the Company's lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™ (plasminogen), on lung fibrosis indications, at the American Thoracic Society (ATS) 2019 International Conference taking place in Dallas, Texas , from May 17 – 22, 2019. "These pre-clinical results provide additional evidence demonstrating the anti-fibrotic activity of PBI-4050, and its potential as a novel therapy for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Importantly, PBI-4050 has now been demonstrated to reduce fibrosis in two models of pulmonary fibrosis, commented Dr. Lyne Gagnon, Vice President of Preclinical R&D at Prometic.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of PLI.TO earnings conference call or presentation 9-May-19 12:30pm GMT

    Q1 2019 Prometic Life Sciences Inc Earnings Call

  • CNW Grouplast month

    Prometic announces terms of equity rights offering

    LAVAL, QC , May 15, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") is pleased to confirm the terms of its previously announced equity rights offering for gross proceeds of up to $75,000,000 (the "Rights Offering"). The Corporation will be offering rights to the holders of record of its outstanding common shares (the "Common Shares") at the close of business on May 21, 2019 (the "Record Date"), on the basis of one right for each Common Share held, on the terms summarized hereafter and more fully detailed in the Corporation's rights offering circular which will be available under Prometic's profile at www.sedar.com (the "Rights Offering Circular"). Each right will entitle the holder to subscribe for up to twenty (20) Common Shares upon payment of a subscription price rounded to the nearest 5 decimals of $0.01521 per Common Share, subject to proration as described below.

  • CNW Grouplast month

    Prometic reports its 2019 first quarter financial results

    LAVAL, QC , May 8, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") reported today its unaudited financial results for the first quarter ended March 31, 2019 . "We are pleased to have completed the recapitalization transactions and equity offering in April that have provided both an improved capital structure and necessary cash liquidity from the $ 75 million  gross proceeds received from Structured Alpha LP and Consonance Capital Management", stated Mr. Kenneth Galbraith , Chief Executive Officer. "We made excellent progress during the quarter towards completing the necessary development work to permit re-filing of our Ryplazim™ (plasminogen) ("RyplazimTM ") BLA before the end of 2019.

  • CNW Grouplast month

    Prometic strengthens its leadership with a new management structure and the appointment of three new directors

    LAVAL , QC and CAMBRIDGE, United Kingdom , May 8, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or "Corporation") is pleased to announce today a new management structure to provide leadership to the Corporation  and the appointment of Dr. Gary Bridger , Mr. Timothy Wach and Mr. Neil Klompas to the Board of Directors. All three of these individuals will be included as nominees for election to the Board of Directors by shareholders at the upcoming Annual General and Special Meeting of the shareholders ("AGM") scheduled to take place in Montreal , Québec, Canada on June 19, 2019 .

  • CNW Group2 months ago

    Prometic Completes Refinancing Transactions Including C$75 Million (approximately US$56 Million) in Gross Proceeds from New Equity Financing

    LAVAL, QC , April 23, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") is pleased to announce today's closing of the recapitalization and equity offering previously announced on April 15, 2019 . Prometic received C$75 million (approximately US$56 million ) in gross proceeds from the equity offering led by Consonance Capital Management ("Consonance") and Structured Alpha LP ("SALP") and converted into equity substantially all of its indebtedness to SALP. Prometic is also pleased to announce the appointment of Stefan Clulow , Managing Director and Chief Investment Officer of Thomvest Asset Management, as Chair of Prometic's Board of Directors and Kenneth Galbraith as Chief Executive Officer.  Concurrent with these leadership changes, Professor Simon Best has been appointed Prometic's Lead Independent Director, and Dr. Benny Soffer , of Consonance, has been designated as a Prometic board observer.

  • Reuters2 months ago

    CANADA STOCKS-TSX rises as financials, energy stocks gain

    Canada's main stock edged higher on Tuesday, lifted by financials and energy stocks as positive economic data from major economies fueled risk appetite, while a drop in gold kept a check on further gains. ...

  • CNW Group2 months ago

    Prometic Announces Refinancing Transactions

    LAVAL, QC , April 15, 2019  /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") announced today its intention to enter into a series of related arrangements to restructure Prometic's outstanding indebtedness, reduce its interest and certain other payment obligations, and raise sufficient cash to build a robust balance-sheet for the next phase of Prometic's development. "These transactions will strengthen our balance sheet, allowing Prometic to bring its first products to market and advance its very promising small-molecule pipeline," said Professor Simon Best , Chairman and Interim CEO.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PLI.TO earnings conference call or presentation 2-Apr-19 3:00pm GMT

    Q4 2018 Prometic Life Sciences Inc Earnings Call

  • Reuters2 months ago

    CANADA STOCKS-TSX set to end 5-day rally as financials fall, USMCA worries

    Canada's main stock index was on track to snap a five-day run of gains on Monday after financial stocks declined and as the chances of ratifying a pact between the United States, Mexico and Canada this ...

  • Reuters2 months ago

    CANADA STOCKS-Energy shares drive TSX to seven-month highs

    Canada's main stock index rose for the fifth straight session on Friday as energy stocks gained and a rebound in U.S. jobs growth in March eased slowdown concerns in the world's largest economy. * At 9:40 ...

  • Reuters2 months ago

    CANADA STOCKS-TSX subdued after three-day rally as gold miners slide

    A three-day rally in Canada's main stock index stalled on Thursday, as shares of precious metal miners slipped and investors waited for further progress in U.S.-China trade talks. * At 9:41 a.m. ET , the ...

  • PR Newswire3 months ago

    Prometic reports fourth quarter and 2018 year-end financial results

    LAVAL, QC, April 1, 2019 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic or the Corporation) reported today its financial results for the fourth quarter and year-ended December 31, 2018. Total revenues for the year ended December 31, 2018 were $47.4 million compared to $39.1 million during the comparative period of 2017, which represents an increase of $8.3 million. Total revenues for the quarter ended December 31, 2018 were $10.6 million compared to $6.6 million during the comparative period of 2017, representing an increase of $4.0 million.

  • CNW Group3 months ago

    Prometic to Report its Fourth Quarter and 2018 Year-End Financial Results and Hold Conference Call / Webcast

    LAVAL, QC , March 26, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") announced today that it  will report its financial results for the fourth quarter and year ended December 31, 2018 on Monday April 1, 2019 after market close. Prometic (www.prometic.com) is a biopharmaceutical corporation with two drug discovery platforms focusing on unmet medical needs. The first platform (small molecule therapeutics) stems from the discovery of two receptors which we believe are at the core of how the body heals: namely, promoting tissue regeneration and scar resolution as opposed to fibrosis.

  • CNW Group3 months ago

    Prometic secures additional USD $5 million (CAD $6.7 million) tranche from structured Alpha LP, an affiliate of Thomvest Asset Management Inc., under its existing credit facilities

    LAVAL, QC , March 25, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") announced today that it has secured an additional USD $5 million (CAD $6.7 million ) tranche from Structured Alpha LP ("SALP"), an affiliate of Thomvest Asset Management Inc., under the existing loan agreement originally entered into with SALP in November 2017 . The proceeds of this loan extension will be used to satisfy the near-term cash requirements of the Corporation.